Mark J. Alles
Chairman and Chief Executive Officer
Mark J. Alles became Chief Executive Officer as of March 1, 2016 and joined the Celgene Board of Directors in February 2016. The role of Chairman was added in February 2018.
Mr. Alles served as President and Chief Operating Officer from August 2014 until February 2016, Executive Vice President and Global Head of Hematology & Oncology from December 2012 until July 2014 and was also Celgene’s Chief Commercial Officer. Mr. Alles joined Celgene in April 2004 and was Vice President, Global Hematology Marketing until March 2009 when he was promoted to President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Before joining Celgene, he was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rh?ne-Poulenc Rorer) from 1993-2004.
Mr. Alles began his thirty-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He is a member of the Board of Directors of the Pharmaceutical Manufacturers of America (PhRMA). Mr. Alles earned his B.S. degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps?.
President, Global Hematology & Oncology
Nadim Ahmed was named President, Global Hematology & Oncology Franchise in August 2017. Previously, he was President of Worldwide Markets for the Hematology & Oncology Franchise. Mr. Ahmed served as General Manager, U.S. Hematology & Oncology from August 2014 until March 2016. He joined Celgene in 2010 as Global Head of Marketing for Celgene’s Multiple Myeloma Franchise after holding positions of increasing responsibility in Clinical Development, Medical Affairs, Global and U.S. Marketing at GlaxoSmithKline. Mr. Ahmed has over 25 years of industry experience.
Mr. Ahmed holds a B.S. degree in Pharmacology from University College London, UK and an M.S. in Information Technology from Loughborough University, UK. He serves on the Board of Directors of Family Promise, a not-for-profit organization helping homeless families.
Jay T. Backstrom, M.D., M.P.H.
Chief Medical Officer
Dr. Jay Backstrom became Chief Medical Officer in April 2016. Prior to that he served as Senior Vice President, Clinical R&D and Regulatory Affairs where he was responsible for the late stage clinical and regulatory programs across the Hematology & Oncology portfolio.
Dr. Backstrom joined Celgene in March 2008 as Vice President, Clinical R&D after serving as Vice President, Global Medical Affairs and Safety for Pharmion. Prior to joining Pharmion in 2002, Dr. Backstrom was with Marion Merrell Dow and its successor companies including Hoechst Marion Roussel Surveillance and Pharmacoepidemiology.
Dr. Backstrom received his M.D. from Temple University School of Medicine. He did his post graduate training in Internal Medicine at Temple University Hospital and earned an M.S. in Public Health from Saint Louis University School of Public Health. Before entering the biopharmaceutical industry in 1990, Dr. Backstrom served as staff physician and Medical Director of the Samuel U Rodgers Community Health Center in Kansas City, Missouri.
Richard Bagger, J.D.
Executive Vice President, Corporate Affairs and Market Access
Rich Bagger joined Celgene in 2012 and is responsible for communications, patient advocacy, government relations and policy, market access strategy, global health and corporate responsibility. Before joining Celgene, Mr. Bagger served as Chief of Staff for New Jersey Governor Chris Christie and was responsible for managing implementation of the Governor’s policy agenda and priorities. Mr. Bagger’s public service also includes eleven years in the New Jersey State Legislature, where he was Chair of the Appropriations Committee and was elected by his colleagues as Majority Conference Leader.
Previously, Mr. Bagger was employed by Pfizer for more than 16 years in a series of positions of increasing responsibility within the company’s U.S. Pharmaceuticals, Corporate Affairs and Worldwide Pharmaceuticals Divisions.
Mr. Bagger received an A.B. degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a J.D. from Rutgers University Law School.
Joanne Beck, Ph.D.
Executive Vice President, Pharmaceutical Development and Ops
Dr. Joanne Beck joined Celgene in April 2016. Previously, Dr. Beck was Senior Vice President of Pharmaceutical Development at Shire. Before joining Shire in 2012 she held positions of increasing responsibility in Abbott’s Global Pharmaceutical Operations and was the site head of Abbott Vascular Instruments GmbH. Prior to Abbott, Dr. Beck held positions in Process Development at Genentech and Amgen.
Dr. Beck holds a B.A. degree in Chemistry from Lewis and Clark College, a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco. She serves on the Board of Directors for Orchard Therapeutics.
Jonathan Biller, J.D.
Executive Vice President and General Counsel
Jonathan Biller was appointed Executive Vice President and General Counsel in July 2018 and is responsible for Celgene’s global legal function. Mr. Biller joined Celgene in 2011, serving as Senior Vice President, Tax and Treasury responsible for Celgene’s global tax and treasury functions including the company’s capital allocation strategy and tax policy. Prior to Celgene, Mr. Biller was General Counsel, Chief Tax Officer and Secretary from 2008 to 2011 at Bunge Limited, a publicly traded agriculture and food company. Prior to Bunge, Mr. Biller held roles of increasing responsibility at Alcon, Inc during which time it was a publicly traded company. He began his legal career at Hopkins & Sutter rising to the level of partner and was also a partner at Foley & Lardner after the firms merged.
Mr. Biller also serves on the Board of Junior Achievement New Jersey. He holds a B.A. degree from Brown University and a J. D. from Yale Law School.
Toni-Ann Citera, J.D.
Senior Vice President, Chief Compliance Officer
Toni Citera joined Celgene in June 2018. Prior to Celgene, Ms. Citera worked at Jones Day for 20 years as an associate and then partner. During her time at Jones Day, she represented companies in high-stakes civil and criminal investigations and litigation, with a focus primarily on the pharmaceutical, life sciences, and health care industries. She litigated and counseled clients in matters involving the False Claims Act (FCA), the Anti-Kickback Statute, the Food, Drug, and Cosmetic Act, RICO, and statutory and common law fraud.
Ms. Citera earned her B.A. degree in Political Science and Economics from Syracuse University and her J.D. from Northwestern University.
President, Global Inflammation & Immunology
Terrie Curran became President, Global Inflammation & Immunology Franchise in April 2017. Previously, she was Head of Worldwide Markets for the I&I Franchise. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA?. Prior to joining Celgene, she was Merck’s Senior Vice President and General Manager of the Global Women’s Health Franchise from 2009-2013. Ms. Curran previously served as GM for Schering-Plough Switzerland, which subsequently merged with Merck. Ms. Curran was also GM of Schering-Plough Australia/New Zealand and served on the Asia Pacific Regional Management Team. She joined Schering-Plough (Australia) as Director of Specialty Health Care, where she successfully launched Remicade. Earlier in her career she served in a variety of sales, marketing and management roles at the former Pharmacia.
Ms. Curran holds a B.A.S. degree and a Graduate Diploma of Marketing from the University of Technology, Sydney. Ms. Curran was elected to the Board of directors of BioNJ in February 2018. She also serves on the Board of Directors at Myovant Sciences, Ltd.
Jennifer Dudinak, Pharm.D.
Senior Vice President, Global Regulatory Affairs
Jennifer Dudinak joined Celgene in April 2018. Previously Ms. Dudinak was at GlaxoSmithKline (GSK) for seven years where she was Vice President and Head of Regulatory Affairs for the Pharma Therapeutic Team. She also served as Vice President of Global Regulatory Affairs for Oncology at GSK. Prior to joining GSK, Ms. Dudinak was at Roche/Genentech for over 15 years.
Ms. Dudinak holds a B.S. degree in Pharmacy and a Pharm.D. from Rutgers University. She is also a graduate of Rutgers University/Ernest Mario College of Pharmacy Post-Doctoral Fellowship Program. Ms. Dudinak has also practiced in community, retail and hospital pharmacy as well as being a founding member of Heart to Hearts, a non-profit women’s wellness organization with the aim to empower women through education.
Executive Vice President and Chief Financial Officer
David Elkins joined Celgene in July 2018. He came to Celgene from Johnson & Johnson (J&J), where he was Worldwide Vice President and Chief Financial Officer for Consumer Products, Medical Devices and Corporate Functions. Prior to J&J, Mr. Elkins was CFO for Round Rock Research, a technology investigation and patent licensing company. From 2008 to 2012, Mr. Elkins was Executive Vice President and CFO of Becton, Dickinson and Company, a public global medical technology company. From 1995 to 2008, he held roles of increasing responsibility at AstraZeneca, and he began his career in finance at the Boeing Company in 1991.
Mr. Elkins holds a B.S. degree from the University of Delaware, an M.S. from the University of Pennsylvania and an M.B.A. from Drexel University.
Joseph Hand, J.D.
Executive Vice President, Global Human Resources & Corporate Services
Joe Hand became the head of Global Human Resources and Corporate Services functions in September 2017. Mr. Hand is responsible for all employee-related activities including talent development & learning, diversity & inclusion, employee engagement and compensation & benefits. He is also responsible for the management of Celgene’s global facilities footprint, which includes offices and research facilities in more than 40 countries. Under Mr. Hand’s leadership, Celgene transformed its approach to talent acquisition, talent management and talent development and has been recognized as a top employer by Forbes and numerous other independent third parties. Mr. Hand led the integration of Juno Therapeutics, a $9 billion-dollar acquisition of a late-stage CAR T therapy company and he has recruited many key executive leaders to the company.
Prior to his current position, Mr. Hand held cross-functional roles, serving as Chief of Staff to the Chairman and Chief Executive Officer and worked as an attorney in our legal department. He joined Celgene in 2011. Before Celgene, Mr. Hand was a litigation attorney at the international law firm of Jones Day. His clients included Fortune 500 companies in the financial services, life-sciences, chemical and commercial manufacturing industries.
Mr. Hand holds a B.B.A. degree in Accounting and Computer Applications from the University of Notre Dame and a J.D. from New York University School of Law.
Robert Hershberg, M.D., Ph.D.
Executive Vice President, Head of Business Development & Global Alliances
Dr. Rob Hershberg became Executive Vice President, Head of Business Development & Global Alliances in March 2017. Prior to his current role, Dr. Hershberg served as Chief Scientific Officer. He joined Celgene in August 2014 to lead the scientific and early clinical efforts in Immuno-Oncology (I-O).
Before joining Celgene, Dr. Hershberg was the President and Chief Executive Officer of VentiRx Pharmaceuticals, which he co-founded in 2006. Prior to co-founding VentiRx, Dr. Hershberg served as Senior Vice President and CMO at Dendreon Corporation where he led the clinical, regulatory and biometrics groups, focusing on the development of Provenge? in metastatic prostate cancer. From 2001 to 2003, Dr. Hershberg was the Vice President of Medical Genetics at Corixa, a pharmaceutical company (acquired by GlaxoSmithKline in 2005). Earlier in his career, Dr. Hershberg served as an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women’s Hospital in Boston, Massachusetts.
Dr. Hershberg earned his B.A. degree in molecular biology and M.D. at University of California Los Angeles, and his Ph.D. in biology at the Salk Institute. Dr. Hershberg holds clinical and research faculty positions at the University of Washington School of Medicine. He serves on the Board of Directors of Adaptive Biotechnologies Corp., Nanostring Technology and Silverback Therapeutics.
Peter N. Kellogg
Executive Vice President and Chief Corporate Strategy Officer
Peter Kellogg became Executive Vice President and Chief Corporate Strategy Officer of Celgene in August 2018. Mr. Kellogg joined Celgene as Chief Financial Officer in August 2014. Before joining Celgene, he was EVP and CFO of Merck & Co. Inc. from 2007 to 2014. From 2000 to 2007, Mr. Kellogg served as EVP and CFO of Finance at Biogen, Inc. Earlier in his career, Mr. Kellogg was a member of the PepsiCo Management for 13 years. He was the Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc. in 2000 and SVP and CFO, Frito-Lay International, from 1998 to 2000. Before that, he held various General Manager and CFO roles in Frito-Lay and Pepsi Cola in the US, Europe, Asia, and Latin America. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Booz Allen Hamilton and Arthur Andersen & Co.
Mr. Kellogg received his B.S.E. degree from Princeton University in 1978 and M.B.A. from The Wharton School in 1982. Since 2007, Mr. Kellogg has served on the Board of Directors of Yield10 (formerly Metabolix, Inc), a public bioscience company focused on developing step change improvements to crop yields to enhance global food security.
Alise Reicin, M.D.
President, Global Clinical Development
Dr. Alise Reicin joined Celgene as President of Global Clinical Development in November 2018. She came to Celgene from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, where she was most recently Senior Vice President and Head of Global Clinical Development in Research and Development (R&D). At EMD Serono from 2015 to 2018, Dr. Reicin was responsible for clinical development of assets across oncology and inflammatory indications and led clinical development, biostatistics, clinical operations, and the Japan and China R&D hubs. Prior to joining EMD Serono, Dr. Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck, Sharp & Dohme (Merck). Before joining Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.
Dr. Reicin has a B.S. degree in biochemistry from Barnard College of Columbia University and received her M.D. from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology). Dr. Reicin serves on the Board of Directors of Homology Medicines, Inc.
Aijaz “Jazz” Tobaccowalla
Senior Vice President, Chief Information & Digital Officer
Jazz Tobaccowalla joined Celgene in August 2018. Previously, Mr. Tobaccowalla was Chief Information Officer at Regeneron where he was responsible for redesigning and rebuilding the IT organization. Before joining Regeneron, Mr. Tobaccowalla served as Managing Director of Pfizer, Inc. in Mumbai, India where he was responsible for all of Pfizer’s commercial-related activities in India, Bangladesh, Nepal, and Sri Lanka. Before joining Pfizer, Mr. Tobaccowalla was Vice President R&D Business Systems & Strategy at Wyeth. In addition, he led the International Information Services and Global Systems organization at Wyeth, where he directed the information technology program for Wyeth affiliates in Europe, the Middle-East, Africa, Asia-Pacific, Latin America and Canada.
Mr. Tobaccowalla holds a B.S. degree from Ramapo College of NJ and an M.B.A. from the Stern School of Business at New York University.
Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil.
President, Research & Early Development
Dr. Rupert Vessey joined Celgene in January 2015 as Senior Vice President, Translational Development. Before joining Celgene, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck. During his ten years with Merck, Dr. Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics. Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.
Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (M.A.), Clinical Medicine (B.M., B.Ch.) and a Doctor of Philosophy (D.Phil.) in Molecular Immunology. He is an elected Fellow of the Royal College of Physicians and serves on the Board of Directors of Bio-Techne Corporation.